Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP/PKA/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats.
Yu S, Doycheva DM, Gamdzyk M, Yang Y, Lenahan C, Li G, Li D, Lian L, Tang J, Lu J, Zhang JH
Activating the MC1R receptor with a specific drug reduces brain inflammation and improves neurological outcomes in rats after oxygen deprivation injury. This protective effect relies on the cAMP/PKA/Nurr1 signaling pathway, as blocking Nurr1 eliminates the benefit.
- MC1R activation reduces brain damage and inflammation in rat models of hypoxic-ischemic injury.
- The neuroprotective effect requires functional Nurr1, linking MC1R to NR4A2 pathways.
- CRISPR knockout of Nurr1 reverses the benefits of MC1R activation.
- This study uses neonatal rats, not humans or NR4A2 mutation models.
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease.
Contaldi E, Magistrelli L, Milner AV, Cosentino M, Marino F, Comi C
This study measures NR4A2 levels in immune cells of Parkinson's patients to see if they predict motor complications, but it does not test treatments or address the neurodevelopmental aspects of NR4A2 syndrome. The findings are specific to adult-onset Parkinson's disease and do not translate to clinical management for children with NR4A2-related disorders.
- NR4A2 levels in T cells differ between Parkinson's patients with and without motor complications.
- The study focuses on immune system changes, not brain development or motor function in children.
- Results do not inform treatment strategies for NR4A2 syndrome.
- This is observational research in adults, not a clinical trial or pediatric study.
Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients.
Cossais F, Schaeffer E, Heinzel S, Zimmermann J, Niesler B, Röth R, Rappold G, Scharf A, Zorenkov D, Lange C, Barrenschee M, Margraf NG, Ellrichmann M, Berg D, Böttner M, Wedel T
Researchers find that rectal tissue from Parkinson's disease patients shows altered gene expression related to nerve and mitochondrial function compared to healthy controls. This suggests that intestinal neuropathological changes are common in Parkinson's but does not provide information specific to NR4A2-related syndromes or potential treatments for them.
- Study analyzes rectal biopsies from Parkinson's patients and healthy controls.
- Altered gene expression found in 9 out of 12 Parkinson's patients.
- Changes involve neuroglial, mitochondrial, and inflammatory pathways.
- Findings confirm intestinal neuropathology is common in Parkinson's disease.
- No data on NR4A2 variants or specific therapies for this syndrome.
Lipoic acid alleviates LPS‑evoked PC12 cell damage by targeting p53 and inactivating the NF‑κB pathway.
Mao J, Gao H, Bai W, Zeng H, Ren Y, Liu Y, Yang X
Lipoic acid reduces inflammation and cell death in a Parkinson's disease cell model by blocking specific stress pathways. This study uses rat nerve cells to show that lipoic acid can protect against inflammatory damage, but it does not test this treatment in humans or children with NR4A2 syndrome.
- The study uses rat PC12 cells, not human patients or NR4A2-specific models.
- Lipoic acid reduced inflammatory markers and cell death in the lab setting.
- No clinical data exists for lipoic acid treatment in humans with this syndrome.
- Findings are preclinical and do not translate to immediate therapeutic options.
Research on developing drugs for Parkinson's disease.
Zhang CL, Han QW, Chen NH, Yuan YH
This review outlines various molecular targets and drug development strategies for Parkinson's disease, including Nurr1 (NR4A2), but does not present new clinical data or specific treatments for NR4A2-related syndromes. It highlights that current dopaminergic therapies remain symptomatic while exploring novel mechanisms like immunotherapy and glutamate receptor modulation.
- Nurr1 is identified as one of several emerging molecular targets for Parkinson's drug development.
- Current treatments are limited to symptomatic relief with significant side effects.
- The review covers both preclinical studies and clinical improvements in dopaminergic drugs.
- Immunotherapy and shared pathological mechanisms with Alzheimer's and diabetes are also discussed.
Adolescent oxycodone exposure inhibits withdrawal-induced expression of genes associated with the dopamine transmission.
Carpenter MD, Manners MT, Heller EA, Blendy JA
Adolescent exposure to oxycodone causes lasting changes in brain gene activity related to dopamine, which may increase vulnerability to addiction later in life. These changes are driven by epigenetic mechanisms that silence dopamine-related genes long after drug use stops.
- Oxycodone in adolescence alters dopamine gene expression long-term
- Epigenetic marks suppress brain genes involved in reward
- Changes persist into adulthood, unlike in adult exposure
- This may increase addiction risk due to disrupted brain development
Identification of Pathways and Key Genes in Venous Remodeling After Arteriovenous Fistula by Bioinformatics Analysis.
Jie K, Feng W, Boxiang Z, Maofeng G, Jianbin Z, Zhaoxuan L, Yangyi Z, Liang C, Haobo S, Wensheng L, Guoping C, Jianping G, Xu H, Jianyan W
This study identifies NR4A2 as a gene that increases in human veins when they adapt to high blood flow from dialysis fistulas. The research focuses on vascular biology and does not address the neurological or developmental aspects of NR4A2-related syndromes.
- NR4A2 expression increases in human veins after arteriovenous fistula creation.
- The study analyzes venous remodeling mechanisms for dialysis access maturation.
- No findings relate to brain development, dopamine neurons, or NR4A2 syndrome phenotypes.
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
Munoz-Tello P, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ
This study identifies which previously reported drugs actually bind directly to the NR4A2 protein and reveals that many do not. It also shows that these compounds affect gene activity through mechanisms unrelated to NR4A2, complicating their use as targeted therapies.
- Only amodiaquine, chloroquine, and cytosporone B bind directly to the NR4A2 protein.
- Nine other tested ligands do not bind NR4A2 despite affecting gene transcription.
- Many ligands influence transcription independently of NR4A2 in a cell-specific manner.
- Results clarify which compounds are valid starting points for drug development.
NURR1 Alterations in Perinatal Stress: A First Step towards Late-Onset Diseases? A Narrative Review.
Bordoni L, Petracci I, Calleja-Agius J, Lalor JG, Gabbianelli R
This narrative review discusses how perinatal stress and environmental factors can alter NURR1 expression, potentially linking early-life events to late-onset diseases. It proposes NURR1 as a prognostic marker or therapeutic target but does not present new clinical data or treatment results for NR4A2-related syndromes.
- NURR1 mediates responses to perinatal stress and influences dopaminergic neuron development.
- Maternal inflammation and neurotoxins alter NURR1 expression in gestational tissues.
- The paper reviews potential links between early NURR1 changes and adult diseases.
- No clinical trials or human patient outcomes for NR4A2 variants are reported.
DNA methylation and psychotherapy response in trauma-exposed men with appetitive aggression.
Xulu KR, Womersley JS, Sommer J, Hinsberger M, Elbert T, Weierstall R, Kaminer D, Malan-Müller S, Seedat S, Hemmings SMJ
This study links changes in DNA methylation of the NR4A2 gene to reduced PTSD symptoms in adults undergoing psychotherapy for trauma-related aggression. It does not provide evidence on NR4A2 syndrome development, treatment efficacy for children, or genetic mechanisms specific to pediatric neurodevelopmental disorders.
- Study focuses on adult men with trauma and appetitive aggression, not children.
- NR4A2 methylation changes correlate with PTSD symptom reduction in psychotherapy patients.
- Research examines epigenetic responses to therapy, not NR4A2 syndrome pathology.
- Findings do not translate to pediatric neurodevelopmental outcomes or treatments.
Effect of selected bisphenol derivatives on nuclear receptor expression in ovarian cell line COV434.
Mlynarcikova AB, Scsukova S
This study shows that common plastic chemicals can alter the expression of NURR1 in human ovarian cells, but it provides no information on how this affects brain development or NR4A2-related syndromes. The findings are limited to cell culture experiments and do not translate to clinical outcomes for children with genetic variants.
- Bisphenol chemicals increased NURR1 mRNA levels in human ovarian cells at high concentrations.
- The study used a granulosa cell line, not brain or neural tissue relevant to NR4A2 syndromes.
- No changes occurred in other nuclear receptors or cell viability during the experiment.
- Results do not inform treatment, prognosis, or phenotype for NR4A2-related disorders.
Complex regulation of orphan nuclear receptor Nur77 (Nr4a1) transcriptional activity by SUMO2 and PIASγ.
Dodat F, Cotnoir-White D, Dianati E, Vallet A, Mader S, Lévesque D
This study details how specific molecular switches (SUMOylation) regulate the activity of Nur77, a protein closely related to NR4A2. It identifies distinct regulatory mechanisms for Nur77 that differ from those controlling Nurr1 (NR4A2). The findings provide basic mechanistic insight into nuclear receptor biology but do not offer direct clinical guidance or treatment options for NR4A2-related syndromes.
- SUMO2 and PIASγ repress Nur77 transcriptional activity in cell cultures.
- Specific mutations at lysine sites alter how SUMOylation affects Nur77 function.
- Nur77 regulation differs significantly from its homolog Nurr1 (NR4A2).
- The research focuses on molecular mechanisms without clinical or therapeutic implications.
Seasonal differences in the transcriptome profile of the Zhedong white goose (Anser cygnoides) pituitary gland.
Zhao W, Yuan T, Fu Y, Niu D, Chen W, Chen L, Lu L
This study found that gene activity in goose pituitary glands changes with the seasons, especially around key times like spring and summer when breeding starts. Genes linked to reproduction, stress response, and hormone signaling shift in expression, helping explain how geese time their breeding to maximize offspring survival.
- Pituitary gene activity varies with seasons in geese
- NR4A2 and other transcription factors change seasonally
- Hormone receptors and stress genes are involved in breeding timing
- Oxidative stress and steroid pathways support seasonal reproduction
- Findings help explain how light cues control breeding cycles
The nuclear receptor 4A family members: mediators in human disease and autophagy.
Chen L, Fan F, Wu L, Zhao Y
This review summarizes how NR4A1, NR4A2, and NR4A3 regulate autophagy and contribute to various human diseases. It highlights that understanding these mechanisms may eventually aid in developing new therapies.
- The paper reviews the roles of three NR4A family members in disease and autophagy.
- It discusses how NR4A proteins act as gene regulators in signaling pathways.
- Better understanding of these mechanisms could improve future drug development processes.
- The content is a broad overview rather than specific clinical guidance for NR4A2 syndrome.
Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration.
Jennings E, Elliot TAE, Thawait N, Kanabar S, Yam-Puc JC, Ono M, Toellner KM, Wraith DC, Anderson G, Bending D
This study shows that different Nr4a family genes in T cells respond to immune signals in distinct ways, with Nr4a1 being more sensitive to weak or brief signals than Nr4a3. The findings reveal how T cell development and function are shaped by the strength and duration of immune activation, which may influence immune-related disorders.
- Nr4a1 responds to weaker T cell signals than Nr4a3
- Nr4a1 is activated during early T cell development
- T cell signal duration affects immune cell fate
- NFAT1 controls Nr4a2 and Nr4a3 expression
- These genes may influence immune system regulation
Epinephrine May Contribute to the Persistence of Traumatic Memories in a Post-traumatic Stress Disorder Animal Model.
Martinho R, Oliveira A, Correia G, Marques M, Seixas R, Serrão P, Moreira-Rodrigues M
Epinephrine appears to help maintain traumatic memories in a PTSD mouse model, likely by increasing the activity of the Nr4a2 and Nr4a3 genes in the brain. Removing epinephrine reduced fear behaviors, and giving it back restored those memories, showing a direct role in memory persistence.
- Epinephrine strengthens traumatic memories in PTSD models
- Nr4a2 and Nr4a3 genes increase with epinephrine in the hippocampus
- Mice without epinephrine show less fear and anxiety-like behavior
- Giving epinephrine back restores fear memories in these mice
- This suggests epinephrine may block memory extinction in PTSD
Gene expression in the epileptic (EL) mouse hippocampus.
Lee TS, Li AY, Rapuano A, Mantis J, Eid T, Seyfried TN, de Lanerolle NC
This study analyzes gene expression changes in the hippocampus of a mouse model of epilepsy to understand how glial cells contribute to seizures. It identifies specific molecular pathways involving heat shock proteins and immediate early genes, including NR4A2, that may drive neuronal hyperexcitability.
- The EL mouse model lacks neuron loss but shows glial activation, isolating neuroglia's role in seizures.
- NR4A2 expression increases alongside other immediate early genes linked to hippocampal hyperexcitability.
- Activated microglia may remove inhibitory synapses, reducing neuronal inhibition and favoring seizures.
- Astrocyte deficiency in glutamine synthetase reduces glutamate clearance, potentially worsening excitability.
Differential Expression of microRNA Profiles and Wnt Signals in Stem Cell-Derived Exosomes During Dopaminergic Neuron Differentiation.
Jin T, Gu J, Xia H, Chen H, Xu X, Li Z, Yue Y, Gui Y
Exosomes from stem cells promote the production of dopamine-producing neurons in mouse models. The study identifies specific microRNAs and Wnt signaling pathways within these exosomes that drive this differentiation process.
- Exosomes from epiblast-derived stem cells boost dopamine neuron generation in mouse embryonic stem cells.
- Twenty-six microRNAs change expression during this differentiation, with most increasing significantly.
- Wnt signaling and extracellular matrix interactions are key pathways involved in the process.
- Nine dopamine neuron marker genes increase in exosomes as differentiation progresses.
NR4A2 Exacerbates Cerebral Ischemic Brain Injury via Modulating microRNA-652/Mul1 Pathway.
Liu Q, Dong Q
NR4A2 worsens brain damage after stroke by reducing a protective microRNA, which in turn increases a protein that promotes cell death and cell cycle arrest. This pathway may offer a target for future treatments to protect the brain during stroke.
- NR4A2 increases brain injury after stroke
- NR4A2 reduces microRNA-652
- Lower microRNA-652 raises Mul1 protein
- Mul1 causes cell death and arrest
- Blocking this pathway could be protective
Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation.
Weber-Stadlbauer U, Richetto J, Zwamborn RAJ, Slieker RC, Meyer U
Maternal immune activation in mice causes opposite dopaminergic effects across generations, with first-generation offspring showing hyperdopaminergia and later generations showing blunted responses. These changes correlate with altered DNA methylation of the Nurr1 gene in sperm and brain tissue.
- First-generation mouse offspring show increased dopamine sensitivity after maternal immune activation.
- Second- and third-generation offspring display reduced dopamine responses to stimulants.
- Nurr1 gene methylation increases in sperm of first-generation and brains of later generations.
- Epigenetic changes in male germline may drive transgenerational dopaminergic dysfunction.
Human Mesenchymal Stromal Cells Unveil an Unexpected Differentiation Potential toward the Dopaminergic Neuronal Lineage.
Gaggi G, Di Credico A, Izzicupo P, Alviano F, Di Mauro M, Di Baldassarre A, Ghinassi B
This study shows that stem cells derived from the placenta can be converted into cells that resemble midbrain dopaminergic neurons in a laboratory dish. The resulting cells express key markers like NURR1 and produce dopamine, demonstrating a potential new source for cell replacement therapies.
- Placental stem cells differentiate into neuron-like cells expressing dopaminergic markers.
- The cells express NURR1, PITX3, and other midbrain-specific transcription factors.
- This offers an alternative to pluripotent stem cells for generating dopamine neurons.
- The research is preclinical and conducted entirely in cell culture systems.
Global gene expression profile of periodontal ligament cells submitted to mechanical loading: A systematic review.
Spitz A, Christovam IO, Marañón-Vásquez GA, Masterson DF, Adesse D, Maia LC, Bolognese AM
This study looked at how mechanical pressure affects gene activity in cells from the periodontal ligament, finding that genes like NR4A2 are involved in responses to mechanical stress. These findings suggest NR4A2 and other genes may serve as biomarkers for tooth movement during orthodontic treatment.
- NR4A2 is linked to mechanical stress response in periodontal cells
- Mechanical loading changes gene activity related to cell growth and tissue remodeling
- 3D culture models show stronger gene responses than 2D models
- Findings may help understand orthodontic tooth movement mechanisms
- More standardized studies are needed for definitive results
The Extracts of Human Fetal Brain Induce the Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Dopaminergic Neuron Containing Cells.
Li Y, Yang J, Li M, Zhang X, Du J, Zhao X, Xu Z, Lin J
This study demonstrates that human umbilical cord stem cells can be converted into dopamine-producing neuron-like cells in a laboratory dish using extracts from human fetal brain tissue. The method establishes a potential new cell source for treating neurodegenerative diseases like Parkinson's, though it remains an early-stage experimental finding.
- Human umbilical cord stem cells differentiate into neuron-like cells when treated with fetal brain extracts.
- Induced cells express key dopaminergic markers including Nurr1, LMX1B, and dopamine transporter.
- The technique offers a new in vitro method for generating dopamine-producing cells.
- Results are preclinical and do not involve human patients or clinical trials.
Carbon Fibers as a New Type of Scaffold for Midbrain Organoid Development.
Tejchman A, Znój A, Chlebanowska P, Frączek-Szczypta A, Majka M
Carbon fiber scaffolds improve the survival and differentiation of midbrain dopaminergic neurons in organoid cultures compared to traditional polymer materials. This finding establishes a better in vitro model for studying neurodegenerative diseases like Parkinson's, but it does not provide direct clinical insights or treatments for NR4A2-related syndromes.
- Carbon fibers support midbrain dopaminergic neuron survival better than PLGA scaffolds.
- The study uses induced pluripotent stem cells to create organoid models in vitro.
- PITX3 gene expression correlates with the health of these specific neurons.
- This work creates a tool for Parkinson's research, not a therapy for NR4A2.
- No human participants or clinical data are involved in this study.
Origin of the Induced Pluripotent Stem Cells Affects Their Differentiation into Dopaminergic Neurons.
Chlebanowska P, Sułkowski M, Skrzypek K, Tejchman A, Muszyńska A, Noroozi R, Majka M
The type of skin or blood cell used to create stem cells changes how well those cells turn into dopamine-producing neurons in lab dishes. This technical detail matters for researchers trying to model diseases like NR4A2 syndrome using patient-specific stem cells, but it does not offer a treatment.
- Stem cell origin affects gene expression during early neuron development.
- Blood-derived and skin-derived stem cells behave differently in lab models.
- This is basic laboratory methodology research with no clinical application.
- It does not test treatments or analyze human patient outcomes.
Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson's Disease.
Odumpatta R, Arumugam M
This computational study identifies NR4A2 as one of several hub genes in Parkinson's disease networks, alongside Protein Kinase C (PRKACB) and other signaling molecules. The analysis suggests these genes interact with specific transcription factors and microRNAs to influence disease pathways.
- NR4A2 appears as a hub gene in Parkinson's disease network models.
- Protein Kinase C (PRKACB) is highlighted as a significant druggable target.
- The study uses bioinformatics, not human or animal experiments.
- No clinical data or treatment outcomes for NR4A2-related syndromes are presented.
CD4+ T-cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.
De Francesco E, Terzaghi M, Storelli E, Magistrelli L, Comi C, Legnaro M, Mauri M, Marino F, Versino M, Cosentino M
This study measures immune cell gene expression in Parkinson's disease research and does not provide information on NR4A2-related syndromes or treatments. It finds no direct evidence relevant to the genetic cause or management of your child's condition.
- The study focuses on Parkinson's disease, not NR4A2-related syndromes.
- Researchers analyzed immune cells from Parkinson's patients and healthy controls.
- NR4A2 appears only as one of many measured genes in T-cells.
- Findings do not inform diagnosis or treatment for NR4A2 variants.
The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs.
Willems S, Kilu W, Ni X, Chaikuad A, Knapp S, Heering J, Merk D
This study identifies several non-steroidal anti-inflammatory drugs as inverse agonists that reduce Nurr1 activity, providing new chemical tools to study its mechanism. It demonstrates that Nurr1 can be regulated bidirectionally and recruits different co-regulators depending on whether it is activated or inhibited.
- NSAIDs act as inverse agonists, reducing Nurr1 transcriptional activity.
- Nurr1 recruits specific co-regulators in a ligand-dependent manner.
- Dimerization states distinguish between agonist and inverse agonist effects.
- Findings offer chemical tools for future drug discovery targeting Nurr1.
Nurr1 performs its anti-inflammatory function by regulating RasGRP1 expression in neuro-inflammation.
Oh M, Kim SY, Gil JE, Byun JS, Cha DW, Ku B, Lee W, Kim WK, Oh KJ, Lee EW, Bae KH, Lee SC, Han BS
This study identifies RasGRP1 as a new target gene that Nurr1 regulates to control inflammation in immune cells. It shows that Nurr1 binds directly to the RasGRP1 gene to manage inflammatory signaling pathways.
- Nurr1 directly binds to the RasGRP1 gene intron to regulate its expression.
- RasGRP1 controls the Ras-Raf-MEK-ERK signaling cascade during inflammation.
- The research uses BV2 microglial cells and LPS-induced inflammation models.
- This is a molecular mechanism study with no human or clinical data.
Genome-Wide Analysis Identifies NURR1-Controlled Network of New Synapse Formation and Cell Cycle Arrest in Human Neural Stem Cells.
Kim SM, Cho SY, Kim MW, Roh SR, Shin HS, Suh YH, Geum D, Lee MA
This study maps the direct genetic targets of NURR1 in human neural stem cells, revealing that the protein regulates networks controlling synapse formation and cell cycle arrest. It confirms that NURR1 expression correlates with processes essential for midbrain dopaminergic development, such as neuronal migration and stopping cell division.
- Researchers identified approximately 40 direct target genes controlled by NURR1 in human neural stem cells.
- NURR1 promotes gene expression linked to new synapse formation and neuronal cell migration.
- NURR1 negatively correlates with genes driving cell cycle progression and DNA replication.
- Findings align with known roles of NURR1 in midbrain dopaminergic neurogenesis.
Transfer of pathological α-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure.
Meng Y, Ding J, Li C, Fan H, He Y, Qiu P
This study shows that methamphetamine exposure causes neurons to release pathological alpha-synuclein via exosomes, which astrocytes absorb and trigger inflammatory responses. The research finds that this process reduces Nurr1 (NR4A2) expression in astrocytes, suggesting a link between drug-induced neurotoxicity and inflammation.
- Methamphetamine causes neurons to release alpha-synuclein inside exosomes.
- Astrocytes absorb these exosomes and develop inflammatory responses.
- Alpha-synuclein accumulation in astrocytes decreases Nurr1 expression.
- Nurr1 reduction may drive inflammation after methamphetamine exposure.
Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors.
García-Martínez A, Fuentes-Fayos AC, Fajardo C, Lamas C, Cámara R, López-Muñoz B, Aranda I, Luque RM, Picó A
Certain microRNAs are more active in silent corticotroph tumors than in functioning ones, suggesting they may help suppress hormone production. These microRNAs could be targets for future treatments to control tumor behavior.
- miR-200a and miR-103 are higher in silent tumors
- miR-383 links to TBX19, a key hormone regulator
- Larger tumors show higher levels of several miRNAs
- These miRNAs may help explain why some tumors don't produce hormones
- Targeting these miRNAs could lead to new therapies
Triphenyltin chloride reduces the development of rat adrenal cortex during puberty.
Li X, Li L, Chen X, Li X, Wang Y, Zhu Q, Gao-Smith F, Ge RS
Triphenyltin exposure reduces adrenal hormone production in rats by blocking cholesterol transport and synthesis, which are critical for hormone development during puberty. This effect is linked to the down-regulation of NR4A2 and other key genes involved in adrenal function.
- Triphenyltin lowers corticosterone and ACTH levels in pubertal rats
- NR4A2 and other transcription factors are suppressed by triphenyltin
- Cholesterol transport and synthesis genes are down-regulated
- NR4A1, LDLR, and HMGCS1 protein levels decrease
- Oxidative stress increases, but no cell death occurs
Weighted gene co-expression network analysis to investigate the key genes implicated in global brain ischemia/reperfusion injury in rats.
Ma D, Qiao J, Qu Q, He F, Chen W, Yu B
This study identifies NR4A2 as a key gene downregulated in rat brains following global ischemia/reperfusion injury, linking it to brain damage mechanisms rather than developmental function. The research focuses on acute stroke-like injury pathways in rodents and does not address the neurodevelopmental aspects of NR4A2 syndrome.
- NR4A2 levels decrease in rat hippocampus after global ischemia/reperfusion injury.
- Study uses rodent models to investigate brain damage from reduced blood flow.
- No human data, clinical cohorts, or developmental phenotypes are included.
- Findings relate to acute injury mechanisms, not NR4A2-related neurodevelopmental disorders.
Genetic Architecture and Molecular Neuropathology of Human Cocaine Addiction.
Huggett SB, Stallings MC
This study identifies NR4A2 as one of several genes differentially expressed in the brains of individuals with cocaine use disorder, linking it to dopamine neurotransmission pathways. It does not provide new information about NR4A2-related syndromes or potential treatments for children with this condition.
- NR4A2 shows altered expression in postmortem brain tissue from adults with cocaine addiction.
- The research focuses on drug use disorder, not developmental disorders or pediatric phenotypes.
- No clinical trials, genetic screening of NR4A2 variants, or therapeutic interventions are reported.
- Findings relate to adult neurobiology of addiction rather than childhood neurodevelopment.
Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth.
Hannan NJ, Stock O, Spencer R, Whitehead C, David AL, Groom K, Petersen S, Henry A, Said JM, Seeho S, Kane SC, Gordon L, Beard S, Chindera K, Karegodar S, Hiscock R, Pritchard N, Kaitu'u-Lino TJ, Walker SP, Tong S
This study identifies NR4A2 mRNA in maternal blood as a biomarker for severe placental insufficiency and fetal acidemia, not as a cause of NR4A2-related syndrome. The findings relate to pregnancy complications rather than the genetic condition affecting the child.
- NR4A2 mRNA levels in maternal blood correlate with severe placental insufficiency.
- The study focuses on fetal growth restriction and stillbirth risk, not NR4A2 syndrome.
- NR4A2 acts here as a biomarker for placental health, not a disease gene.
- No clinical implications exist for managing NR4A2-related syndromes in children.
Correction: Direct Regulation of Pitx3 Expression by Nurr1 in Culture and in Developing Mouse Midbrain.
Volpicelli F, De Gregorio R, Pulcrano S, Perrone-Capano C, di Porzio U, Bellenchi GC
This study confirms that Nurr1 directly controls the expression of Pitx3, a gene critical for midbrain development, in both cell cultures and developing mice. It corrects previous findings regarding the specific mechanism of this genetic regulation.
- Nurr1 directly regulates Pitx3 expression in mouse midbrain development.
- The paper corrects prior errors in understanding this regulatory pathway.
- Findings are based on cell cultures and animal models, not humans.
- No clinical data or treatment implications for patients are presented.
Dysfunctional Nurr1 promotes high glucose-induced Müller cell activation by up-regulating the NF-κB/NLRP3 inflammasome axis.
Li W, Liu X, Tu Y, Ding D, Yi Q, Sun X, Wang Y, Wang K, Zhu M, Mao J
This study shows that high glucose levels disable Nurr1 in eye cells, triggering inflammation and cell damage in a mouse model of diabetic retinopathy. Treating these mice with a drug that activates Nurr1 reduced nerve cell loss, suggesting this pathway could be a target for eye disease treatment.
- High glucose disables Nurr1, leading to increased inflammation in retinal Müller cells.
- Restoring Nurr1 activity protects retinal ganglion cells in diabetic mice.
- The drug C-DIM12 activates Nurr1 and reduces nerve damage in animal models.
- This research focuses on eye disease mechanisms, not NR4A2-related movement disorders.
LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson's disease via the HPRT1-mediated Wnt/β-catenin signaling pathway.
Jiang J, Piao X, Hu S, Gao J, Bao M
Overexpressing the long non-coding RNA H19 protects dopaminergic neurons in a mouse model of Parkinson's disease by activating the Wnt/beta-catenin signaling pathway. This protective effect occurs because H19 binds to microRNA-301b-3p, which prevents the suppression of HPRT1 and allows for increased expression of key neuronal genes like Nurr-1.
- H19 overexpression reduces dopaminergic neuron loss in Parkinson's disease mouse models.
- The mechanism involves H19 binding to miR-301b-3p to regulate HPRT1 levels.
- HPRT1 activation triggers the Wnt/beta-catenin pathway to support neuronal survival.
- Key dopaminergic genes including Nurr-1, Pitx-3, and NeuroD1 increase with this treatment.
The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice.
Valsecchi V, Boido M, Montarolo F, Guglielmotto M, Perga S, Martire S, Cutrupi S, Iannello A, Gionchiglia N, Signorino E, Calvo A, Fuda G, Chiò A, Bertolotto A, Vercelli A
This study finds that the protein Nurr1 increases in the blood of ALS patients and in the spinal cords of ALS mice, where it acts to reduce inflammation. The research suggests Nurr1 is part of the body's early protective response against neurodegeneration, although this natural mechanism is not strong enough to stop the disease.
- Nurr1 levels rise in the blood of human ALS patients.
- Nurr1 increases in spinal cords of ALS mice during early disease stages.
- Nurr1 reduces inflammation by suppressing pro-inflammatory targets in mouse models.
- Nurr1 promotes protective factors but cannot reverse ALS progression alone.